With the growing globalization of the legal cannabis industry, Good Manufacturing Practice (GMP) compliance has emerged as a major point of reference for product quality, patient safety, and international trade. GMP, as it is commonly known, is a codified set of rules and regulations that ensure the quality, safety and efficacy of a drug. In this case, we are talking about cannabis. It covers all aspects of the production process and is audited and certified by regulatory agencies. However, regulatory expectations around GMP can vary significantly by jurisdiction and many licensed operators are not prepared for so. Nowhere is this more apparent than in the comparison between United States and European Union GMP frameworks for cannabis. Cannaspire’s Cannabis consultants help operators plan, launch, and stay compliant.
This article will outline the key differences between U.S. state-level cannabis cGMP and EU-GMP, and highlights what cannabis producers need to consider when seeking access to regulated licensed medical markets, especially in Europe. Working with cannabis compliance consulting is one of the most reliable ways to stay audit-ready.
In the U.S., cannabis is classified as a Schedule I substance under the Controlled Substances Act, making it federally illegal. However, as of 2025, over 40 states have legalized cannabis in some form for medicinal and/or adult-use purposes.
Due to the absence of federal oversight, there is no uniform national GMP requirement for cannabis. Instead, GMP standards are defined at the state level and often modeled after federal regulations for food or dietary supplements, such as:
For operators navigating GMP compliance in the U.S. cannabis market, see our Cannabis GMP Comprehensive Guide.
The EU, however, regulates medical cannabis as either an Active Pharmaceutical Ingredient (API) or Finished Pharmaceutical Product (FPP) depending on the form. As a result, all manufacturers exporting medical cannabis into the EU must adhere to EU-GMP, which is based on:
EU-GMP compliance is legally required for any cannabis-based medicine/product or raw material intended for use in finished pharmaceutical products within EU member countries.
In the EU, compliance is audited and verified by a Qualified Person (QP) and authorized through certification by national authorities, whereas U.S. cannabis manufacturers are often inspected by state regulators using different & inconsistent criteria.
For example, EudraLex Volume 4 Part I applies to finished cannabis medicines, and Part II (ICH Q7) applies to raw cannabis materials used as APIs.
Category | U.S. GMP (State-level) | EU-GMP |
Facility Design |
|
|
Validation |
|
|
Water/Air Quality |
|
|
EU-GMP regulations mandate strict role definitions, primarily the Qualified Person (QP) who is legally responsible for certifying and signing off on each batch. Personnel must be trained under documented SOPs per EU GMP Chapter 2 & Annex 1.
On the other hand, U.S. cannabis facilities rarely require a QP and lack robust documentation unless aiming for FDA-regulated status.
EU-GMP mandates extensive quality control testing under ICH Q6A and method validation under ICH Q2(R1), including:
While U.S. states do require lab testing, the standards, methods, and pesticide limits vary widely per state, and often fall short of ICH or pharmaceutical benchmarks.
Although U.S. cannabis markets are state-regulated and fragmented due to federal prohibition, GMP standards remain a critical matter, especially for international companies aiming to enter the U.S. market and U.S. companies preparing for federal reform.
Although THC-dominant cannabis remains illegal and prohibited under U.S. federal law to import or export, hemp-derived cannabinoids such as CBD and minor cannabinoids (e.g., CBG, CBN) can legally enter the U.S. under certain conditions, provided they contain <0.3% Δ9-THC by dry weight.
For companies exporting these products into the U.S., FDA GMP standards under 21 CFR Part 111 or 117 are increasingly expected for:
While enforcement has been inconsistent, FDA warning letters have cited firms for:
As discussions around federal legalization continue to gain traction in the U.S., cannabis manufacturers should start to think of building out and scaling their operations with cGMP standards under 21 CFR Parts 210/211 (cGMP for drugs), anticipating a regulatory shift. This shift may likely place cannabis products under similar oversight as botanical drugs, biologics, or supplements, depending on classification.
For international companies looking ahead:
Even now, U.S. importers of cannabinoid-based products must ensure that foreign partners follow:
In high-regulation states like California, New York, New Jersey, Massachusetts, and Florida, cannabis regulators are now incorporating GMP language directly into licensing applications, requiring:
Some states reference ISO 22000, Hazard Analysis and Critical Control Points (HACCP), or NSF/ANSI 455 as GMP equivalents, aligning somewhat with international standards.
Due to the EU’s strict import controls, no cannabis material or product can enter the European market without GMP certification for medical cannabis. This includes:
Producers in Canada, Colombia, Israel, and Uruguay have already adapted to EU-GMP to enter the European market. U.S. cannabis companies remain excluded due to federal prohibition, but preparing facilities to meet EU-GMP can future-proof operations in anticipation of legalization or international expansion.
The difference between U.S. and EU GMP requirements highlights the complexity of international cannabis compliance. While the U.S. cannabis industry remains fragmented and state-regulated, the EU operates under a standardized, pharmaceutical-grade regulatory framework.
Cannabis businesses seeking global opportunities, especially in Europe, must align their operations with EudraLex Volume 4, ICH guidelines, and pharmaceutical GMP principles. This often requires significant investment in quality systems, personnel, infrastructure, and third-party consultants & audits, but by doing so, the reward is gaining access to one of the most regulated and potentially lucrative medical cannabis markets in the world.
Want to know if your competitor has EU-GMP certification? Check out the EU-GMP certification database at: eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPCompliance.do
Having the insight of consultants who have experienced multiple GMP programs and inspections can be helpful to ensure best practices from across the industry are taken into consideration. We here at Cannaspire have that experience and are ready to help. See our full range of Cannabis Certification Services here.
Minnesota cannabis buildout guide: the 18-month clock, zoning and local registration, security rules, Metrc onboarding, and OCM inspection readiness.
What it takes to fund a Virginia cannabis business before the February 2027 application window — capital stack, investor structures, CCA disclosure rules, and 280E math.
How hemp operators move into licensed cannabis before the federal 0.4 mg THC cap takes effect: the four realistic paths, what transfers, and what to do in the next 90 days.
